US Branded Generics Market expanding at 9–10% CAGR with support from Indian pharma players by 2027

The US Branded Generics Market was valued at $19.1 billion in 2022 and is set to witness a growth rate of ~9-10% by 2027. Growing number of chronic diseases, surge in ANDA filings and approvals, channel consolidation & deep pricing pressure, portfolio rationalization by MNCs, patent expiry of major drugs, and foray of Indian players are some of the key factors driving the US branded generics market growth. However, higher costs compared to unbranded generics is one of the pivotal factors that are likely to impact the market growth.

Branded generics are generic drugs that are given a proprietary market name. It can be developed either by a generic drug firm or by the original manufacturer and can be marketed after the patent expiry of the original drug. They are sold by using a brand name instead of a chemical name. An abbreviated new drug application (ANDA) is submitted to the regulatory body for marketing branded generics and it should be therapeutically equivalent to the original drug for which the patent is expired.

Download a free sample report now 👉
https://meditechinsights.com/us-branded-generics-market/request-sample/

Advantages Offered By Branded Generics Drives Their Adoption in the US Branded Generics Market

Due to the multiple advantages offered by branded generics, their adoption is expected to rise in the United States. Following are the advantages:-

•  
• They are sold as alternatives to brand-name drugs and are relatively less expensive
• For combination drugs it is difficult to remember their generic names. Branded generics can be easily remembered.
• Attract several consumers who prefer branded drugs only.
• They provide quality assurance from well-established companies.

“Branded generics comprise only a small percentage of total generic prescriptions in the U.S. but they are more profitable than unbranded generics..…”- Tier I Branded Generic Manufacturer, USA

Foray of India Players Adds a Competitive Intensity to the US Branded Generics Market

The share of Indian players in the US branded generics market is expected to further increase in the next five years primarily due to the following:

• High R&D Spend: Large Indian players continue to invest significantly in R&D. Leading Indian players have increased their R&D budgets over the last few years, indicating a good launch pipeline of these players
• Entry of New Indian players: The U.S. market continues to see the entry of new players every year, and these companies are expected to further drive the share of Indian players in overall ANDA approvals
• CDMO Entry: Few Indian CDMOs are also planning to enter the U.S. market
• Focus of Indian players is on specialty/complex generics where competition is relatively lower and launching products early.

Unmet Patient Needs Across Indications Fuels the Growth of the US Branded Generics Market

The unmet patient needs in cardiovascular, gastroenterology,  diabetology, oncology, pain management, and dermatology therapeutic areas drives the US branded generics market. Other application areas that are also witnessing increased demand are women’s health, neurology, ophthalmology, respiratory, hormonal, anti-psychotic, and infectious diseases.

Download a sample report for in-depth competitive insights
https://meditechinsights.com/us-branded-generics-market/request-sample/

Organic and Inorganic Growth Strategies Adopted by Leading Players to Establish Their Foothold in US Branded Generics Market

The leading players operating in the US branded generics market have adopted both organic and inorganic growth strategies such as acquisitions, and partnerships to garner a larger market share.

For instance,

• In November 2021,  ANI Pharmaceuticals completed the acquisition of Novitium Pharma, significantly enhancing its R&D capabilities and scale of generics and CDMO businesses.

The outlook for the US branded generics market looks promising due to the patent expiry of major drugs, the growing prominence of Indian companies, relatively more profitability as compared to unbranded generics, and unmet patient needs across various therapeutic areas.

About Medi-Tech Insights

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the areas of market assessments, due diligence, competitive intelligence, market sizing and forecasting, pricing analysis & go-to-market strategy. Our methodology includes rigorous secondary research combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply side decision-makers.

Contact:

Ruta Halde
 Associate, Medi-Tech Insights
 +32 498 86 80 79
 info@meditechinsights.com